Literature DB >> 8314489

Diagnostic markers of viral hepatitis B and C.

C Trépo1, F Zoulim, C Alonso, M A Petit, C Pichoud, L Vitvitski.   

Abstract

Hepatitis B virus (HBV) serology has become extremely refined. As well as the recognised hepatitis B surface (HBs), hepatitis B core (HBc), and hepatitis B e (HBe) antigen-antibody systems, new markers have been introduced including pre-S1, pre-S2 for the envelope and the functional X protein. New automates have been introduced allowing flexibility in the different tests according to precise needs. The monitoring of pre-S1 antigen provides a relevant correlate of viral replication. The quantitative determination of HBV-DNA, pre-S1 Ag, and IgM anti-HBc seem most useful for the decision to use, and the monitoring of, antiviral treatment. Second generation ELISAs detect antibodies to three sets of hepatitis C virus (HCV) protein including the c22 core, and c33, and c100, which correspond to the non-structural regions (NS3 and NS4, respectively). Second generation ELISAs require confirmation by supplement assays, but their biggest limitation is the delayed appearance of anti-HCV after primary infection. In addition 10% of chronic infections with liver disease still remain seronegative despite circulating HCV RNA in serum or liver, or both. Much progress still has to be made before HCV serology can reach the level of sophistication of HBV.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8314489      PMCID: PMC1373999          DOI: 10.1136/gut.34.2_suppl.s20

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  27 in total

1.  Replication capacities of natural and artificial precore stop codon mutants of hepatitis B virus: relevance of pregenome encapsidation signal.

Authors:  S P Tong; J S Li; L Vitvitski; C Trépo
Journal:  Virology       Date:  1992-11       Impact factor: 3.616

2.  Antibody to superoxide dismutase, autoimmune hepatitis, and antibody tests for hepatitis C virus.

Authors:  Y Ikeda; G Toda; N Hashimoto; K Kurokawa
Journal:  Lancet       Date:  1990-06-02       Impact factor: 79.321

3.  False-positive hepatitis C virus antibody tests in paraproteinaemia.

Authors:  D Boudart; J C Lucas; J Y Muller; D Le Carrer; B Planchon; J L Harousseau
Journal:  Lancet       Date:  1990-07-07       Impact factor: 79.321

4.  X antigen/antibody markers in hepadnavirus infections. Presence and significance of hepadnavirus X gene product(s) in serum.

Authors:  M A Feitelson; M M Clayton; B S Blumberg
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

5.  Autoimmune chronic active hepatitis: changing reactivity for antibodies to hepatitis C virus after immunosuppressive treatment.

Authors:  R Schvarcz; M von Sydow; O Weiland
Journal:  Scand J Gastroenterol       Date:  1990-11       Impact factor: 2.423

6.  Possible prevention of chronic hepatitis B by early interferon therapy.

Authors:  C Trépo; I Chemin; M A Petit; P Chossegros; F Zoulim; P Chevallier; M Sepetjan
Journal:  J Hepatol       Date:  1990       Impact factor: 25.083

7.  Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region.

Authors:  S P Tong; J S Li; L Vitvitski; C Trépo
Journal:  Virology       Date:  1990-06       Impact factor: 3.616

8.  Variable expression of preS1 antigen in serum during chronic hepatitis B virus infection: an accurate marker for the level of hepatitis B virus replication.

Authors:  M A Petit; F Zoulim; F Capel; S Dubanchet; C Dauguet; C Trepo
Journal:  Hepatology       Date:  1990-05       Impact factor: 17.425

9.  Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result?

Authors:  I G McFarlane; H M Smith; P J Johnson; G P Bray; D Vergani; R Williams
Journal:  Lancet       Date:  1990-03-31       Impact factor: 79.321

10.  Type 2 autoimmune hepatitis and hepatitis C virus infection.

Authors:  M Lenzi; G Ballardini; M Fusconi; F Cassani; L Selleri; U Volta; D Zauli; F B Bianchi
Journal:  Lancet       Date:  1990-02-03       Impact factor: 79.321

View more
  8 in total

1.  Occurrence of false positives during testing for antibodies to hepatitis C virus among volunteer blood donors in India.

Authors:  Sukanya Raghuraman; Thenmozhi Subramaniam; Dolly Daniel; Gopalan Sridharan; Priya Abraham
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

2.  Prevalence of hepatitis A, B, and C markers in school children of a rural area of Crete, Greece.

Authors:  C Lionis; E Frangoulis; M Koulentakis; E Biziagos; E Kouroumalis
Journal:  Eur J Epidemiol       Date:  1997-06       Impact factor: 8.082

3.  The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function.

Authors:  C F Kollmorgen; A P Meagher; B G Wolff; J H Pemberton; J A Martenson; D M Illstrup
Journal:  Ann Surg       Date:  1994-11       Impact factor: 12.969

4.  Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections.

Authors:  Y Y Zhang; J Summers
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 5.  Applications of human hepatitis B virus preS domain in bio- and nanotechnology.

Authors:  Riki Toita; Takahito Kawano; Jeong-Hun Kang; Masaharu Murata
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

Review 6.  Development of resistance and perspectives for future therapies against hepatitis B infections: lessons to be learned from HIV.

Authors:  K Deres; H Rübsamen-Waigmann
Journal:  Infection       Date:  1999       Impact factor: 3.553

7.  Reactivity of genotype-specific recombinant proteins of human erythrovirus B19 with plasmas from areas where genotype 1 or 3 is endemic.

Authors:  Armen Parsyan; Shane Kerr; Shirley Owusu-Ofori; Gordon Elliott; Jean-Pierre Allain
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

8.  Interleukin-21 receptor gene polymorphism is associated with hepatitis B virus-related hepatocellular carcinoma in Chinese patients.

Authors:  Tangyuheng Liu; Jiajia Song; Mei Zhang; Siyue Li; Jinya Zhang; Xuejiao Hu; Zhenzhen Zhao; Wu Peng; Qian Wu; Hao Bai; Yinyu Li; Xiaojun Lu; Binwu Ying
Journal:  J Clin Lab Anal       Date:  2019-02-13       Impact factor: 2.352

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.